arrow
D

David Sacerdoti

university of verona
H指数:45
被引数:7,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database

2024年意大利慢性乙型肝炎和德尔塔病毒诊断患者的估计:基于国家真实世界数据库的研究

2025-09-040
OAAI
Outcome of hepatic resection for HCC in ideal and non-ideal candidates

理想和非理想候选者行肝切除治疗HCC的结局

2025-07-290
OA
The prognostic impact of comorbidities in patients with hepatocellular carcinoma: a multicenter observational study
2025-03-010
PRE
Statins in patients with advanced hcc treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from arte an Italian prospective multicentric dataset
2025-02-010
PRE
Outcome of hepatic resection for hepatocellular carcinoma in ideal and non-ideal candidates
2025-02-010
PRE
Prevalence and impact of Clinically Significant Portal Hypertension (CSPH) in patients with Hepatocellular Carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database
2025-02-010
PRE
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma

丙型肝炎病毒复制缺失与抗HCV阳性肝细胞癌患者预后改善相关

2025-01-080
OAAI
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study

MASLD患者的等待名单死亡率和5年移植生存获益: 一项意大利肝移植登记研究

2024-09-012
OAAI
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE